On 28th August 2023, Stayble Therapeutics announced the enrollment of the first patient in
CROMSOURCE Regulatory Newsletter January – March 2023
CROMSOURCE announces publication of its latest Regulatory Newsletter summarising important
Stayble Therapeutics receives approval to start Phase Ib clinical trial with STA363 for the treatment of herniated discs
On 28th February 2023, Stayble Therapeutics AB announced that the Company received approval
Dialco Medical Inc. Engages CROMSOURCE as CRO Partner for DIMI IDE Trial
CROMSOURCE Announces Appointment of Kris O’Brien as Global Head of TalentSource Life Sciences
CROMSOURCE announced today the appointment of Kris O’Brien as Global Head of TalentSource